BioMarin Pharmaceutical Profit Margin 2006-2021 | BMRN
Current and historical gross margin, operating margin and net profit margin for BioMarin Pharmaceutical (BMRN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. BioMarin Pharmaceutical net profit margin as of September 30, 2021 is 0.86%.
|BioMarin Pharmaceutical Annual Profit Margins
|BioMarin Pharmaceutical Quarterly Profit Margins
||Medical - Biomedical and Genetics
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.